Welcome to our dedicated page for Strata Skin Sciences SEC filings (Ticker: SSKN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STRATA Skin Sciences filings document a dermatology medical-technology issuer whose disclosures cover XTRAC® excimer laser, VTRAC® lamp systems, the TheraClear®X Acne Therapy System, operating results, capital structure and public-company status. Form 8-K reports include quarterly results, investor-presentation materials, Nasdaq continued-listing notices and at-the-market equity offering registration matters.
The filing record also includes proxy materials for director elections, amendments to the 2016 Equity Incentive Plan and auditor ratification. STRATA's Forms 25 and 15 document removal of its common stock from Nasdaq listing and registration under Section 12(b), followed by the certification and notice of termination of Section 12(g) registration and suspension of Exchange Act reporting obligations.
STRATA Skin Sciences develops and markets medical devices for dermatology, led by its XTRAC excimer laser and VTRAC lamp systems for psoriasis, vitiligo and other inflammatory skin diseases, and the TheraClear X acne system. XTRAC in the U.S. is mainly placed under a recurring per-use revenue model with 842 partner clinics as of December 31, 2025.
The company reported a net loss of about $6.3 million for 2025 and an accumulated deficit of about $254.4 million. A Nasdaq delisting in February 2026 triggered an event of default under its MidCap term loan, causing all long‑term debt to be classified as current and creating substantial doubt about its ability to continue as a going concern.
Reimbursement is central to the model: Medicare national CPT rates for XTRAC treatments in 2025 ranged from $137 to $183 per treatment, and revised excimer CPT descriptors effective January 1, 2027 are expected to expand covered indications to additional autoimmune skin conditions. STRATA also faces sales‑tax disputes totaling several million dollars and supply‑chain risks tied to rare gases used in its lasers.
Strata Skin Sciences, Inc. filed a Form 25 notifying the removal of its Common Stock, $0.001 par value from The Nasdaq Stock Market LLC. The filing states the Exchange and the issuer have each complied with the procedures set forth in 17 CFR 240.12d2-2. The notice is dated February 19, 2026 and bears a signature block from John Gillings, Chief Accounting Officer.
Strata Skin Sciences, Inc. plans to delist its common stock from Nasdaq and terminate its SEC reporting obligations after failing to regain compliance with Nasdaq’s minimum $2.5 million stockholders’ equity requirement. Nasdaq has notified the company that trading is expected to be suspended at the opening on February 19, 2026.
The company anticipates filing a Form 25 around February 19, 2026 to deregister under Section 12(b), followed by a Form 15 around March 2, 2026 to begin “going dark” under Sections 12(g), 13(a) and 15(d). Management and the board cite expected time and cost savings, but acknowledge that delisting and going dark will likely make the stock more illiquid and harder for stockholders to sell.